Evidence map›Paper›PMID 36778024›Full record

ArticleFrontiers in pharmacology2023

Photodynamic therapy in combination with immune checkpoint inhibitors plus chemotherapy for first-line treatment in advanced or metastatic gastric or gastroesophageal junction cancer: A phase 2-3 clinical trial protocol.

Yang Yu, Rong Yu, Na Wang, Yuping Bai, Qianling Shi, Ewetse Paul Maswikiti, Hao Chen

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. PDT and antitumor immunity: the beginnings of the story.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Review
  6. Review
  7. Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang YuThe Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Rong YuThe Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Na WangThe Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Yuping BaiThe Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Qianling ShiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Ewetse Paul MaswikitiThe Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Hao ChenThe Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chemotherapyclinical trialsgastric cancerimmune checkpoint inhibitorphotodynamic therapy

Identifiers

PMID36778024
PMCPMC9908746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.